Early Phase 1 N=24 Age-Related Effects of THC
Tolerance · Adolescent Behavior · THC
Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=33 Behavioral Pharmacology of THC and Alpha-pinene
THC · Alpha-pinene
Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale
Phase 1 N=35 Behavioral Pharmacology of THC and D-limonene
D-limonene and THC Pharmacodynamics
Primary: Mean Peak Change From Baseline Anxiety as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 13.8; 18.7; -1.9 score on a scale
Phase 2 N=25 Effects of Dronabinol (Oral THC) on Cannabis Use
Marijuana Smoking
Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
N/A N=190 Using Imaging to Assess Effects of THC on Brain Activity
Intoxication Alcohol · Intoxication THC · Intoxication Combined Alcohol THC
Primary: Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans of Patients Completing the N-back Task. — 0.00000000042; -0.00000000126…
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
Phase 2 N=34 Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Pain Threshold · Mood
Primary: Pain Tolerance — 6.1; 2.8; 4.9; 1.5 seconds
Early Phase 1 N=60 Individual Differences in Drug Response
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Primary: Change From Baseline in Profile of Mood States (POMS) — 2.58; 4.28; 8.25; 0.7 units on a scale
Phase 1 N=12 Ph1 Marinol Interaction Study - Part 2 - 1
Marijuana Dependence
Primary: Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects. — 6; 6 participants
Phase 3 N=160 An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients
Multiple Sclerosis
Primary: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment — -25.32; -19.32 units on a scale — p=0.124
Early Phase 1 N=72 Developing a Mobile Method to Measure THC-induced Impairment
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Primary: Simple Reaction Time — .365; .386; .396 Seconds
Phase 2 N=7 Trial of Cannabis for Essential Tremor
Essential Tremor
Primary: Digital Spirography — 1.04; 1.00 millimeters of tremor amplitude
Phase 4 N=46 Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study
PostTraumatic Stress Disorder
Primary: Brain Measures — 0.039567327; 0.092173636; 0.149446357; -0.021618 arbitrary units — p=< 0.05
N/A N=199 Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail
Alcohol Drinking · Marijuana Smoking
Primary: Alcohol Use, Average # of Drinks Per Week — 11.16; 10.62; 5.16; 3.86 average # of drinks per week
Phase 2 N=199 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
Cannabis Intoxication
Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001
Phase 2 N=17 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
Tourette Syndrome
Primary: Changes in Tic Severity — 7.6 score on a scale
Phase 2 N=14 Effects of Marijuana on Symptoms of OCD
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive-Compulsive Challenge Scale (YBOC-CS) — 17.45; 17.00; 17.09; 13.36 score on a scale — p=.577
Phase 2 N=5 Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain
Cannabis · HIV Neuropathy · Pain Syndrome
Primary: Phase 1 - Numerical Pain Rating Scale (NPRS) — 2.2; 2.6; 2.8; 1.4 units on a scale
N/A N=253 Pain Research: Innovative Strategies With Marijuana
Chronic Pain · Chronic Low Back Pain · Cannabis Use
Primary: Pain Interference: Roland Morris Disability Questionnaire (RMDQ) — 8.028; 9.635; 9.034; 6.194 score on a scale
Phase 3 N=154 An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Mean Part A Primary Impairment Visual Analogue Scale Score (After 6 Weeks) at the End of Four Weeks of Open-label Treatment (10 Weeks Total) — -5.41; -7.51…
Phase 2 N=80 Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
Posttraumatic Stress Disorder
Primary: Baseline CAPS-5 Total Severity Score — 36.6; 36.8; 38.0; 37.3 score on a scale
Phase 2 N=131 Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain
Cannabis · Low Back Pain · Neuropathic Pain
Primary: Numerical Pain Intensity — 6.03; 6.11; 6.24; 5.97 score on a scale — p=0.78
N/A N=62 Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
Smoking
Primary: Maximum Concentration (Cmax) of Nicotine Following Single Use of mTHS, mCC and NRT — 10.70; 12.09; 7.64; 7.52 ng/mL
N/A N=28 Individual Differences in the Response to Drugs
Healthy
Primary: Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration — 4.79; 12.83; 11.08; 12.17 units on a scale
Phase 1 N=10 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Cannabis Use Disorder
Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
N/A N=62 Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
Smoking
Primary: Maximum Concentration (Cmax) of Nicotine Following Single Use of THS 2.2, CC and NRT — 14.30; 13.82; 11.53; 4.80 ng/mL